The influences of dose and ethnic origins on the pharmacokinetics of nifedipine

The pharmacokinetics of nifedipine capsules was investigated in healthy young Caucasian and South Asian subjects. Both the area under the plasma concentration–time curve (AUC) and terminal half‐life of nifedipine were significantly higher in South Asians compared with Caucasian subjects after single oral doses of 10 and 20 mg. The AUC and half‐life values of the nitropyridine metabolite were also higher in South Asians than in Caucasian subjects. The serum protein binding of nifedipine was similar in the two groups. The pharmacokinetics were essentially linear in both Caucasian subjects (0 to 30 mg; n= 27) and South Asians (0 to 20 mg; n= 16). There was no indication of a separate subgroup of Caucasian subjects with high AUC values equivalent to the poor metabolizers reported previously. Pharmacodynamic modeling for South Asians gave estimates comparable to those previously reported in Caucasian subjects. Patients of South Asian origin may require lower doses of nifedipine.

[1]  J. Kolars,et al.  First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.

[2]  A G Renwick,et al.  The pharmacokinetics of oral nifedipine--a population study. , 1988, British journal of clinical pharmacology.

[3]  A. Renwick,et al.  The first pass metabolism of nifedipine in man. , 1984, British journal of clinical pharmacology.

[4]  D. Breimer,et al.  Nifedipine: Kinetics and dynamics in healthy subjects , 1984, Clinical pharmacology and therapeutics.

[5]  D. Breimer,et al.  Nonlinear first-pass metabolism of nifedipine in healthy subjects. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  M. Danhof,et al.  The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. , 1989, British journal of clinical pharmacology.

[7]  A G Renwick,et al.  The influence of posture on the pharmacokinetics of orally administered nifedipine. , 1992, British journal of clinical pharmacology.

[8]  R. Ziegler,et al.  Plasma concentration‐response relationships for some cardiovascular effects of dihydropyridines in healthy subjects , 1988, Clinical pharmacology and therapeutics.

[9]  A. Renwick,et al.  Ethnic differences in the pharmacokinetics of oral nifedipine. , 1991, British journal of clinical pharmacology.

[10]  L. Lesko,et al.  Protein binding of nifedipine , 1986, The Journal of pharmacy and pharmacology.

[11]  G. Castañeda-Hernández,et al.  Pharmacokinetics of Nifedipine Slow Release Tablet in Mexican Subjects: Further Evidence for an Oxidation Polymorphism , 1989, Journal of clinical pharmacology.

[12]  J. Mucklow,et al.  Contribution of environmental factors to variability in human drug metabolism. , 1979, Drug metabolism reviews.

[13]  G. Wilkinson,et al.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. , 1990, British journal of clinical pharmacology.

[14]  V. R. Richards,et al.  Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects , 1983, Journal of clinical pharmacology.

[15]  J. Feely.  Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. , 1984, British journal of clinical pharmacology.

[16]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[17]  D. Back,et al.  Cyclosporin metabolism by the gastrointestinal mucosa. , 1991, British journal of clinical pharmacology.

[18]  F. Guengerich.  Oxidative cleavage of carboxylic esters by cytochrome P-450. , 1987, The Journal of biological chemistry.

[19]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[20]  W. Kalow,et al.  Ethnic Differences in Drug Metabolism , 1982, Clinical pharmacokinetics.

[21]  J. Mucklow,et al.  The relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani immigrants to Britain. , 1982, British journal of clinical pharmacology.

[22]  C. Bulpitt,et al.  Environmental effects on antipyrine half‐life in man , 1977, Clinical pharmacology and therapeutics.

[23]  M. Danhof,et al.  Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration , 1986, Clinical pharmacology and therapeutics.

[24]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[25]  Y. Lou.  Differences in drug metabolism polymorphism between Orientals and Caucasians. , 1990, Drug metabolism reviews.

[26]  M. J. Coon,et al.  The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. , 1989, DNA.

[27]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[28]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[29]  E. Lee,et al.  Evidence for the polymorphic oxidation of debrisoquine in the Thai population. , 1990, British journal of clinical pharmacology.

[30]  Honghao Zhou,et al.  Ethnic Differences in Drug Disposition and Responsiveness , 1991, Clinical pharmacokinetics.

[31]  M. Danhof,et al.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. , 1984, Biochemical pharmacology.

[32]  M. Eichelbaum.  Defective Oxidation of Drugs: Pharmacokinetic and Therapeutic Implications , 1982, Clinical pharmacokinetics.

[33]  A. Renwick,et al.  The trans-hepatic extraction of nifedipine. , 1987, British journal of clinical pharmacology.

[34]  D. Breimer,et al.  Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. , 1988, Biochemical pharmacology.